1.41
-0.01(-0.70%)
Currency In USD
| Previous Close | 1.42 |
| Open | 1.51 |
| Day High | 1.51 |
| Day Low | 1.4 |
| 52-Week High | 1.96 |
| 52-Week Low | 1.17 |
| Volume | 630 |
| Average Volume | 61,111 |
| Market Cap | 69.4M |
| PE | -5.87 |
| EPS | -0.24 |
| Moving Average 50 Days | 1.45 |
| Moving Average 200 Days | 1.4 |
| Change | -0.01 |
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
GlobeNewswire Inc.
Jan 29, 2026 11:00 PM GMT
LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that as of t
2026 New Year’s Greetings from the CEO
GlobeNewswire Inc.
Jan 06, 2026 2:00 PM GMT
LA JOLLA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) provides shareholders a corpo
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
GlobeNewswire Inc.
Dec 18, 2025 11:00 AM GMT
LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successf